WO2011035569A1 - Process for manufacture of n-acylbphenyl alanine - Google Patents
Process for manufacture of n-acylbphenyl alanine Download PDFInfo
- Publication number
- WO2011035569A1 WO2011035569A1 PCT/CN2010/071243 CN2010071243W WO2011035569A1 WO 2011035569 A1 WO2011035569 A1 WO 2011035569A1 CN 2010071243 W CN2010071243 W CN 2010071243W WO 2011035569 A1 WO2011035569 A1 WO 2011035569A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- salt
- acid
- preparing
- Prior art date
Links
- 0 *C(NCC(O)=O)=O Chemical compound *C(NCC(O)=O)=O 0.000 description 6
- HDNGVBPPMAZUMI-UHFFFAOYSA-N CC(NC(Cc(cc1)ccc1-c1ccccc1)C(O)=O)=O Chemical compound CC(NC(Cc(cc1)ccc1-c1ccccc1)C(O)=O)=O HDNGVBPPMAZUMI-UHFFFAOYSA-N 0.000 description 1
- YUNNBTNVNZITLW-HMMYKYKNSA-N OC(/C(/NC(c1ccccc1)=O)=C\c(cc1)ccc1-c1ccccc1)=O Chemical compound OC(/C(/NC(c1ccccc1)=O)=C\c(cc1)ccc1-c1ccccc1)=O YUNNBTNVNZITLW-HMMYKYKNSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/83—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
Definitions
- the invention relates to a novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, in particular neutral endopeptidase (NEP) inhibitors.
- NEP neutral endopeptidase
- the present invention relates to a method to prepare N-acyl derivatives of biphenyl alanine.
- N-acyl derivatives of biphenyl alanine are key intermediates in the synthesis of pharmaceutically active compounds, in particular neutral endopeptidase (NEP) inhibitors, such as those described in U.S. Patent No. 4,722,810, U.S. Patent No. 5,223,516, U.S. Patent No. 4,610,816, U.S. Patent No.
- NEP neutral endopeptidase
- biphenyl alanine derivatives typically use expensive starting materials such as non-natural D-tyrosine. Moreover, said methods require the use of trifluoromethanesulfonic anhydride, which is also expensive, to activate the phenolic hydroxyl in order to carry out the aryl coupling reaction leading to the desired biphenyl structure.
- trifluoromethanesulfonic anhydride which is also expensive, to activate the phenolic hydroxyl in order to carry out the aryl coupling reaction leading to the desired biphenyl structure.
- This invention provides a method for preparing a N-acylbiphenyl alanine of formula (3), as defined herein.
- the new process, according to the present invention, for producing compounds according to formula (3) is summarized in Scheme 2.
- a compound of formula (1) is obtained.
- Said compound of formula (1) is next converted into a compound of formula (2), as defined herein, which in turn is hydrogenated, for example with hydrogen and palladium on charcoal, to provide the compound of formula (3).
- a compound of formula (3) can be converted into a neutral endopeptidase (NEP) inhibitors, for example, as described in the Journal of Medicinal Chemistry, 1995, Vol. 38, No. 10, 1691, and the patent documents cited hereinbefore, the disclosure for each of which is incorporated by reference
- NEP neutral endopeptidase
- Step a
- the present invention relates to a method for preparing a compound of formula (1-a), or salt thereof, preferably wherein the compound of formula (1-a) is of the formula (1),
- Rl is Ci_ 7 alkyl, preferably methyl, or C 6 _ioaryl, preferably phenyl,
- Rl is as defined for the compound of formula (1-a),
- R2 is Ci_ 7 alkyl, preferably methyl or propyl, most preferably methyl or ethyl,
- solvents generally known in the art, for example, in the presence of a solvent, (named solvent I), selected from benzene, toluene, xylene, chlorobenzene, dichlorobenzene, nitrobenzene, heptane, acetic acid, propionic acid, isobutyric acid, n-butyric acid, acetic anhydride or propionic anhydride.
- solvent I selected from benzene, toluene, xylene, chlorobenzene, dichlorobenzene, nitrobenzene, heptane, acetic acid, propionic acid, isobutyric acid, n-butyric acid, acetic anhydride or propionic anhydride.
- anhydride (B) is acetic anhydride or propionic anhydride.
- under alkaline conditions means that the step requires a base.
- said base is selected from triethylamine, pyridine, N-methylpyrrole, N-methylmorpholine, sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, sodium acetate, potassium acetate, sodium propionate, or potassium propionate.
- step a is carried out at a reaction temperature of from 80 deg C to reflux, preferably, with a reaction time of 0.5 to 48 hours.
- the molar ratio of said biphenyl formaldehyde : said N-acylglycine (A) : said anhydride (B) : said base is 1.0 : (0.7 to 5.0) : (1.0 to 6.0) : (0.05 to 2.00); the amount of said solvent I is 0 to 20 times the weight of feed amount of said biphenyl formaldehyde.
- Step b
- the present invention relates to a method for preparing a compound of formula (2-a), or salt thereof,
- Rl is Ci_ 7 alkyl, preferably methyl, or C 6 -ioaryl, preferably phi
- the reactions described above can be carried out in solvents generally known in the art, for example, in the presence of a solvent, (named solvent II), selected from water, ethanol, methanol, isopropanol, propanol, ethyl acetate, isopropyl acetate, ethyl propionate, acetone, butanone, methyl isobutyl ketone, tetrahydrofuran, 1,4-dioxane, N, N-dimethyl formamide, or N-methylpyrrole.
- a solvent selected from water, ethanol, methanol, isopropanol, propanol, ethyl acetate, isopropyl acetate, ethyl propionate, acetone, butanone, methyl isobutyl ketone, tetrahydrofuran, 1,4-dioxane, N, N-dimethyl formamide, or N-methylpyrrole.
- step b is carried out at a reaction temperature of from room temperature to reflux.
- step c is carried out at a reaction temperature of from room temperature to reflux.
- the present invention relates to a method for preparing a compound of formula (3), or salt thereof, preferably wherein the compound of formula (3) is of the formula (3-a),
- Rl is Ci_ 7 alkyl, preferably methyl, or C 6 -ioaryl, preferably phenyl, comprising
- Rl is Ci_ 7 alkyl, preferably methyl, or C 6 -ioaryl, preferably phenyl,
- Hydrogenation conditions are well-known in the art and thus refer to the use of hydrogen and a transition metal catalyst, for example, as described in Section B.3.3 in WO2009/090251, which is incorporated herein by reference.
- the transition metal catalyst is palladium, preferably palladium on charcoal, preferably containing 1% to 20% palladium by weight.
- the hydrogenation takes place with hydrogen in the presence of a transition metal catalyst comprising an organometallic complex and a chiral ligand, for example as described in Section C.2 in WO2009/090251, which is incorporated herein by reference.
- solvent III selected from ethanol, methanol, ethyl acetate, N, N-dimethyl formamide, N-methylpyrrole and tetrahydrofuran.
- the weight of feed amount of said solvent III is 5 to 50 times of the amount of the compound of formula (1) [named product 1] in step a.
- the amount of palladium on charcoal is 0.1% to 20%> of the compound of formula (2) [named product 2] in step b by weight.
- step c glacial acetic acid is also added in order to maintain acidic conditions.
- the reaction temperature is of from 20 deg C to 150 deg C.
- the pressure of hydrogen is 0.2 MPa to 10.0 MPa.
- the present invention relates to a method for preparing a compound of formula (3), as defined herein, or salt thereof, comprising
- step a) step a), as described above;
- step c) as described above.
- the present invention relates to a method for preparing a compound of formula (3), as defined herein, or salt thereof, comprising
- Embodiment [1] A method for preparing N-acylbiphenyl alanine which is characterized by the following steps:
- Rl is a straight-chain or branched-chain alkyl or aryl and R2 is a methyl or ethyl.
- Embodiment [2] A method for preparing N-acylbiphenyl alanine according to embodiment [1], characterized in that for step a, the molar ratio of said biphenyl formaldehyde: said N-acylglycine: said anhydride: said base is 1.0: (0.7 to 5.0): (1.0 to 6.0): (0.05 to 2.00), and the amount of said solvent I is 0 to 20 times the weight of feed amount of said biphenyl formaldehyde.
- Embodiment [3] A method for preparing N-acylbiphenyl alanine according to embodiment [1], characterized in that for step a, said solvent I is selected from benzene, toluene, xylene, chlorobenzene, dichlorobenzene, nitrobenzene, heptane, acetic acid, propionic acid, isobutyric acid, n-butyric acid, acetic anhydride, or propionic anhydride; said anhydride is acetic anhydride or propionic anhydride; said base is selected from triethylamine, pyridine, N-methylpyrrole, N-methylmorpholine, sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, sodium acetate, potassium acetate, sodium propionate, or potassium propionate.
- said solvent I is selected from benzene, toluene, xylene, chlorobenzene, dichlorobenzene, nitro
- Embodiment [4] A method for preparing N-acylbiphenyl alanine according to embodiment [1], characterized in that step a is carried out at a reaction temperature from 80 deg C to reflux with a reaction time of 0.5 to 48 hours.
- Embodiment [5] A method for preparing N-acylbiphenyl alanine according to embodiment [1], characterized in that for step b, said solvent II is selected from water, ethanol, methanol, isopropanol, propanol, ethyl acetate, isopropyl acetate, ethyl propionate, acetone, butanone, methyl isobutyl ketone, tetrahydrofuran, 1,4-dioxane, N, N-dimethyl formamide, or N-methylpyrrole.
- said solvent II is selected from water, ethanol, methanol, isopropanol, propanol, ethyl acetate, isopropyl acetate, ethyl propionate, acetone, butanone, methyl isobutyl ketone, tetrahydrofuran, 1,4-dioxane, N, N-dimethyl formamide,
- Embodiment [6] A method for preparing N-acylbiphenyl alanine according to embodiment [1], characterized in that for step b, the weight of feed amount of said solvent II is 2 to 50 times the amount of product 1 in step a; the feed amount of said water is 0.5 to 20 times the amount of product 1 in step a.
- Embodiment [7] A method for preparing N-acylbiphenyl alanine according to embodiment [1], characterized in that step b is carried out at a reaction temperature from room temperature to reflux.
- Embodiment [8] A method for preparing N-acylbiphenyl alanine according to embodiment [1], characterized in that for step c, the said solvent III is selected from ethanol, methanol, ethyl acetate, N, N-dimethyl formamide, N-methylpyrrole, or tetrahydrofuran; and said palladium charcoal contains 1% to 20% palladium by weight.
- Embodiment [9] A method for preparing N-acylbiphenyl alanine according to embodiment [1], characterized in that for step c, wherein the weight of feed amount of said solvent III is 5 to 50 times the amount of product 1 in step a, the amount of said palladium charcoal is 0.1% to 20% of the product 2 in step b by weight.
- Embodiment [10] A method for preparing N-acylbiphenyl alanine according embodiment [1], characterized in that glacial acetic acid is also added in order to adjust pH and maintain acidic conditions while step c is carried out, and the range of reaction temperature is from 20 deg C to 150 deg C, and said pressure of hydrogen is 0.2 MPa to 10.0 MPa.
- Alkyl being a radical or part of a radical is a straight or branched (one or, if desired and possible, more times) carbon chain, and is especially Ci-Cy-alkyl, such as Ci-C 4 -alkyl, in particular branched Ci-C 4 -alkyl, such as isopropyl.
- the term "lower” or "C 1 -C7-" defines a moiety with up to and including maximally 7, especially up to and including maximally 4, carbon atoms, said moiety being branched (one or more times) or straight-chained and bound via a terminal or a non-terminal carbon.
- Ci-Cy-alkyl for example, is n-pentyl, n-hexyl or n-heptyl or preferably Ci-C 4 -alkyl, especially as methyl, ethyl, n-propyl, sec-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl, in particular methyl, ethyl, n-propyl, iso-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl. Very preferred is methyl or ethyl.
- Aryl as a radical or part of a radical, for example is a mono- or bicyclic aryl with 6 to 22 carbon atoms, such as phenyl, indenyl, indanyl or naphthyl, in particular phenyl.
- reaction mixture refers to the temperature at which the reaction mixture boils, preferably a temperature up to 180 °C, preferably up to 140 °C.
- room temperature or “ambient temperature” means a temperature of from 20 to 35 °C, such as of from 20 to 25 °C.
- any reference to "compounds", “starting materials” and “intermediates” hereinbefore and hereinafter, is to be understood as referring also to one or more salts thereof or a mixture of a corresponding free compound, intermediate or starting material and one or more salts thereof, each of which is intended to include also any solvate, metabolic precursor such as ester or amide, or salt of any one or more of these, as appropriate and expedient and if not explicitly mentioned otherwise.
- Different crystal forms may be obtainable and then are also included.
- Salts can be formed where salt forming groups, such as basic or acidic groups, are present that can exist in dissociated form at least partially, e.g. in a pH range from 4 to 10 in aqueous solutions, or can be isolated especially in solid, especially crystalline, form.
- salts may be formed preferably with organic or inorganic acids. Suitable inorganic acids are, for example, halogen acids, such as hydrochloric acid, sulfuric acid, or phosphoric acid.
- Suitable organic acids are, for example, carboxylic, phosphonic, sulfonic or sulfamic acids, for example acetic acid, propionic acid, lactic acid, fumaric acid, succinic acid, citric acid, amino acids, such as glutamic acid or aspartic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, benzoic acid, methane- or ethane-sulfonic acid, ethane- 1 ,2-disulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 1 ,5-naphtha- lene-disulfonic acid, N-cyclohexylsulfamic acid, N-methyl-, N-ethyl- or N-propyl-sulfamic acid, or other organic protonic acids, such as ascorbic acid.
- carboxylic, phosphonic, sulfonic or sulfamic acids for example
- salts may be formed with bases, e.g. metal or ammonium salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium, magnesium or calcium salts, or ammonium salts with ammonia or suitable organic amines, such as tertiary monoamines, for example triethylamine or tri(2-hydroxyethyl)amine, or heterocyclic bases, for example
- bases e.g. metal or ammonium salts, such as alkali metal or alkaline earth metal salts, for example sodium, potassium, magnesium or calcium salts
- ammonium salts with ammonia or suitable organic amines, such as tertiary monoamines, for example triethylamine or tri(2-hydroxyethyl)amine, or heterocyclic bases, for example
- salts include the hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric, lactic acid, fumaric acid, succinic acid, oxalic acid, malic acid, malonic acid, tartaric acid, tolyltartaric acid, benzoyltartaric acid, orotic acid, nicotinic acid, methane-sulfonic acid or 4-methylbenzenesulfonic acid salts of compounds of formula (1), (1-a), (2), (2-a), (3), (3-a) and the like formed from reaction with the above reagents.
- Methods to prepare acid addition salts are described in the literature, for example, in the relevant chapters of "CRC Handbook of Optical Resolutions via Diasteromeric Salt
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/497,544 US20130172572A1 (en) | 2008-09-24 | 2010-03-23 | Process for Manufacture of N-acylbiphenyl alanine |
CN201080042243.1A CN102639486B (en) | 2009-09-23 | 2010-03-23 | Process for manufacture of N-acylbphenyl alanine |
IN1968DEN2012 IN2012DN01968A (en) | 2009-09-23 | 2010-03-23 | |
AU2010297892A AU2010297892B2 (en) | 2009-09-23 | 2010-03-23 | Process for manufacture of N-acylbphenyl alanine |
CA2772681A CA2772681C (en) | 2009-09-23 | 2010-03-23 | Process for manufacture of n-acylbphenyl alanine |
KR1020167036201A KR101821090B1 (en) | 2009-09-23 | 2010-03-23 | Process for manufacture of n-acylbiphenyl alanine |
ES10818263.5T ES2627060T3 (en) | 2008-09-24 | 2010-03-23 | Process for the elaboration of N-acyl-biphenyl-alanine |
MX2012003488A MX2012003488A (en) | 2008-09-24 | 2010-03-23 | Process for manufacture of n-acylbphenyl alanine. |
EP10818263.5A EP2480523B1 (en) | 2009-09-23 | 2010-03-23 | Process for manufacture of n-acylbphenyl alanine |
JP2012530106A JP5894531B2 (en) | 2009-09-23 | 2010-03-23 | Process for producing N-acylbiphenylalanine |
RU2012116208/04A RU2534619C2 (en) | 2009-09-23 | 2010-03-23 | Method of obtaining n-acylbiphenylalanine |
BR112012006406A BR112012006406A2 (en) | 2009-09-23 | 2010-03-23 | "Process for the manufacture of n-acylbiphenyl alanine" |
US14/163,526 US9242927B2 (en) | 2008-09-24 | 2014-01-24 | Process for the manufacture of N-acylbiphenyl alanine |
US14/990,832 US20160115118A1 (en) | 2009-09-23 | 2016-01-08 | Process for the manufacture of n-acylbiphenyl alanine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2009/074125 | 2009-09-23 | ||
PCT/CN2009/074125 WO2010034236A1 (en) | 2008-09-24 | 2009-09-23 | Process for the manufacture of n-acylbiphenyl alanine |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/497,544 A-371-Of-International US20130172572A1 (en) | 2008-09-24 | 2010-03-23 | Process for Manufacture of N-acylbiphenyl alanine |
US13497544 A-371-Of-International | 2012-03-22 | ||
US14/163,526 Continuation US9242927B2 (en) | 2008-09-24 | 2014-01-24 | Process for the manufacture of N-acylbiphenyl alanine |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011035569A1 true WO2011035569A1 (en) | 2011-03-31 |
Family
ID=43796233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2010/071243 WO2011035569A1 (en) | 2008-09-24 | 2010-03-23 | Process for manufacture of n-acylbphenyl alanine |
Country Status (11)
Country | Link |
---|---|
US (1) | US20160115118A1 (en) |
EP (1) | EP2480523B1 (en) |
JP (1) | JP5894531B2 (en) |
KR (2) | KR101821090B1 (en) |
CN (1) | CN102639486B (en) |
AU (1) | AU2010297892B2 (en) |
BR (1) | BR112012006406A2 (en) |
CA (1) | CA2772681C (en) |
IN (1) | IN2012DN01968A (en) |
RU (1) | RU2534619C2 (en) |
WO (1) | WO2011035569A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8222286B2 (en) | 2009-11-20 | 2012-07-17 | Novartis Ag | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors |
US8263629B2 (en) | 2009-05-28 | 2012-09-11 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors |
US8394853B2 (en) | 2009-05-28 | 2013-03-12 | Novartis Ag | Substituted aminopropionic derivatives as neprilysin inhibitors |
US9102635B2 (en) | 2013-02-14 | 2015-08-11 | Novartis Ag | Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy |
US9163040B2 (en) | 2013-02-14 | 2015-10-20 | Novartis Ag | Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors |
WO2016128924A1 (en) | 2015-02-13 | 2016-08-18 | Novartis Ag | Process and intermediates for the preparation of nep inhibitors |
WO2017051326A1 (en) | 2015-09-23 | 2017-03-30 | Novartis Ag | New processes and intermediates useful in synthesis of nep inhibitors |
WO2017098430A1 (en) | 2015-12-10 | 2017-06-15 | Novartis Ag | New process and intermediates |
WO2018007919A1 (en) | 2016-07-05 | 2018-01-11 | Novartis Ag | New process for early sacubitril intermediates |
WO2018033866A1 (en) | 2016-08-17 | 2018-02-22 | Novartis Ag | New processes and intermediates for nep inhibitor synthesis |
WO2018116203A1 (en) | 2016-12-23 | 2018-06-28 | Novartis Ag | New process for early sacubitril intermediates |
US10668035B2 (en) | 2018-02-07 | 2020-06-02 | Novartis Ag | Substituted bisphenyl butanoic ester derivatives as NEP inhibitors |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107778192A (en) * | 2016-08-26 | 2018-03-09 | 浙江九洲药业股份有限公司 | A kind of preparation method of N alcoxyls or benzyloxycarbonyl group chirality propylhomoserin |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0212617A1 (en) * | 1985-08-23 | 1987-03-04 | Lederle (Japan) Ltd. | Process for producing 4-biphenylylacetic acid |
WO2004002977A1 (en) * | 2002-07-01 | 2004-01-08 | Pharmacia & Upjohn Company Llc | Inhibitors of hcv ns5b polymerase |
US20040180943A1 (en) * | 2002-07-23 | 2004-09-16 | Augelli-Szafran Corinne Elizabeth | Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis |
WO2009090251A2 (en) | 2008-01-17 | 2009-07-23 | Novartis Ag | New processes |
CN101684077A (en) * | 2008-09-24 | 2010-03-31 | 浙江九洲药业股份有限公司 | Method for preparing N-acyl diphenylalanine |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60185752A (en) * | 1984-03-05 | 1985-09-21 | Mitsui Toatsu Chem Inc | Production of alpha-acetamidocinnamic acid |
JPS60215657A (en) * | 1984-04-10 | 1985-10-29 | Mitsui Toatsu Chem Inc | Preparation of n-acylphenylalanine |
JPS6245554A (en) * | 1985-08-23 | 1987-02-27 | Nippon Redarii Kk | Simple production of 4-biphenylylacetic acid |
FR2662440B1 (en) * | 1990-05-22 | 1992-07-31 | Rhone Poulenc Sante | PROCESS FOR THE STEREOSELECTIVE PREPARATION OF PHENYLISOSERIN DERIVATIVES. |
IL123986A (en) * | 1997-04-24 | 2011-10-31 | Organon Nv | Serine protease inhibiting antithrombotic agents and pharmaceutical compositions comprising them |
GB2354440A (en) * | 1999-07-20 | 2001-03-28 | Merck & Co Inc | Aryl amides as cell adhesion inhibitors |
JP4270484B2 (en) * | 2002-03-08 | 2009-06-03 | 第一ファインケミカル株式会社 | Method for producing optically active phenylalanine derivative |
CN101774941A (en) * | 2009-01-13 | 2010-07-14 | 浙江九洲药业股份有限公司 | Method for preparing and splitting 2-acyl amino-3-biphenylyl propionic acid |
CN101555211B (en) * | 2009-05-13 | 2012-01-25 | 浙江九洲药业股份有限公司 | Chemical synthesis method of 2-acylamino-3-biphenyl propionic acid |
-
2010
- 2010-03-23 CA CA2772681A patent/CA2772681C/en not_active Expired - Fee Related
- 2010-03-23 WO PCT/CN2010/071243 patent/WO2011035569A1/en active Application Filing
- 2010-03-23 KR KR1020167036201A patent/KR101821090B1/en active IP Right Grant
- 2010-03-23 BR BR112012006406A patent/BR112012006406A2/en not_active Application Discontinuation
- 2010-03-23 JP JP2012530106A patent/JP5894531B2/en active Active
- 2010-03-23 EP EP10818263.5A patent/EP2480523B1/en active Active
- 2010-03-23 CN CN201080042243.1A patent/CN102639486B/en active Active
- 2010-03-23 RU RU2012116208/04A patent/RU2534619C2/en not_active IP Right Cessation
- 2010-03-23 IN IN1968DEN2012 patent/IN2012DN01968A/en unknown
- 2010-03-23 AU AU2010297892A patent/AU2010297892B2/en not_active Ceased
- 2010-03-23 KR KR1020127010180A patent/KR20120093227A/en active Application Filing
-
2016
- 2016-01-08 US US14/990,832 patent/US20160115118A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0212617A1 (en) * | 1985-08-23 | 1987-03-04 | Lederle (Japan) Ltd. | Process for producing 4-biphenylylacetic acid |
WO2004002977A1 (en) * | 2002-07-01 | 2004-01-08 | Pharmacia & Upjohn Company Llc | Inhibitors of hcv ns5b polymerase |
US20040180943A1 (en) * | 2002-07-23 | 2004-09-16 | Augelli-Szafran Corinne Elizabeth | Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis |
WO2009090251A2 (en) | 2008-01-17 | 2009-07-23 | Novartis Ag | New processes |
CN101684077A (en) * | 2008-09-24 | 2010-03-31 | 浙江九洲药业股份有限公司 | Method for preparing N-acyl diphenylalanine |
Non-Patent Citations (6)
Title |
---|
DATABASE DATABASE [online] CHEMICAL ABSTRACTS SERVICE; 6 October 1989 (1989-10-06), "4-([1,1'-biphenyl]-4-ylmethylene)-2-methyl-5(4H)-oxazolone", XP008154887, accession no. STN Database accession no. 909768-56-5 * |
GARY M. K. ET AL.: "Dicarboxylic acid dipeptide neutral endopeptidase inhibitors.", J. MED. CHEM., vol. 38, no. 10, May 1995 (1995-05-01), pages 1689 - 1700, XP008154341 * |
JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, no. 10, 1995, pages 1691 |
KHAN, KHALID MOHAMMED ET AL.: "Synthesis and antibacterial and antifungal activity of 5-substituted imidazolones.", LETTERS IN DRUG DESIGN & DISCOVERY, vol. 6, no. 1, January 2009 (2009-01-01), pages 69 - 77, XP008154334 * |
PETKOVA, IRINA ET AL.: "Tuning the excited-state dynamics of GFP-inspired imidazolone derivatives.", J. PHYS. CHEM. A, vol. 114, 12 November 2009 (2009-11-12), pages 10 - 20, XP008154345 * |
See also references of EP2480523A4 |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8263629B2 (en) | 2009-05-28 | 2012-09-11 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors |
US8394853B2 (en) | 2009-05-28 | 2013-03-12 | Novartis Ag | Substituted aminopropionic derivatives as neprilysin inhibitors |
US9006249B2 (en) | 2009-05-28 | 2015-04-14 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors |
US9603819B2 (en) | 2009-05-28 | 2017-03-28 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors |
US8222286B2 (en) | 2009-11-20 | 2012-07-17 | Novartis Ag | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors |
US8377978B2 (en) | 2009-11-20 | 2013-02-19 | Novartis Ag | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors |
US8642635B2 (en) | 2009-11-20 | 2014-02-04 | Novartis Ag | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors |
US8877786B2 (en) | 2009-11-20 | 2014-11-04 | Novartis Ag | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors |
US9480693B2 (en) | 2013-02-14 | 2016-11-01 | Novartis Ag | Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors |
US9163040B2 (en) | 2013-02-14 | 2015-10-20 | Novartis Ag | Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors |
US9102635B2 (en) | 2013-02-14 | 2015-08-11 | Novartis Ag | Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy |
US10112963B2 (en) | 2013-02-14 | 2018-10-30 | Novartis Ag | Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors |
WO2016128924A1 (en) | 2015-02-13 | 2016-08-18 | Novartis Ag | Process and intermediates for the preparation of nep inhibitors |
WO2017051326A1 (en) | 2015-09-23 | 2017-03-30 | Novartis Ag | New processes and intermediates useful in synthesis of nep inhibitors |
WO2017098430A1 (en) | 2015-12-10 | 2017-06-15 | Novartis Ag | New process and intermediates |
US11434192B2 (en) | 2015-12-10 | 2022-09-06 | Novartis Ag | Process and intermediates |
WO2018007919A1 (en) | 2016-07-05 | 2018-01-11 | Novartis Ag | New process for early sacubitril intermediates |
WO2018033866A1 (en) | 2016-08-17 | 2018-02-22 | Novartis Ag | New processes and intermediates for nep inhibitor synthesis |
WO2018116203A1 (en) | 2016-12-23 | 2018-06-28 | Novartis Ag | New process for early sacubitril intermediates |
US10668035B2 (en) | 2018-02-07 | 2020-06-02 | Novartis Ag | Substituted bisphenyl butanoic ester derivatives as NEP inhibitors |
US11426375B2 (en) | 2018-02-07 | 2022-08-30 | Novartis Ag | Substituted bisphenyl butanoic ester derivatives as NEP inhibitors |
Also Published As
Publication number | Publication date |
---|---|
AU2010297892A1 (en) | 2012-03-22 |
JP2013505273A (en) | 2013-02-14 |
EP2480523A4 (en) | 2013-06-26 |
CA2772681C (en) | 2017-01-03 |
KR20120093227A (en) | 2012-08-22 |
EP2480523A1 (en) | 2012-08-01 |
CA2772681A1 (en) | 2011-03-31 |
RU2534619C2 (en) | 2014-11-27 |
IN2012DN01968A (en) | 2015-08-21 |
JP5894531B2 (en) | 2016-03-30 |
CN102639486B (en) | 2014-12-31 |
KR101821090B1 (en) | 2018-01-22 |
EP2480523B1 (en) | 2017-03-01 |
CN102639486A (en) | 2012-08-15 |
BR112012006406A2 (en) | 2016-04-12 |
KR20170002681A (en) | 2017-01-06 |
US20160115118A1 (en) | 2016-04-28 |
AU2010297892B2 (en) | 2014-02-06 |
RU2012116208A (en) | 2013-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2480523B1 (en) | Process for manufacture of n-acylbphenyl alanine | |
US9242927B2 (en) | Process for the manufacture of N-acylbiphenyl alanine | |
CA2749092C (en) | Process for manufacture and resolution of 2-acylamino-3-diphenylpropanoic acid | |
TW201502124A (en) | Method for preparation of benzimidazole derivatives | |
JP2009173621A (en) | Method for producing 2-amino-n-(2,2,2,-trifluoroethyl)acetamide compound or salt thereof | |
MXPA04001837A (en) | Processes for the production of alpha-difluoromethyl ornithine (dfmo). | |
EP2032581B1 (en) | Enantiomerically enriched compounds and process | |
CA2910011A1 (en) | A process for preparing ivabradine | |
TWI719620B (en) | 6-AMINOPYRAZOLO[3,4-d]PYRIMIDINES AND PROCESSES FOR THEIR PREPARATION | |
CN112457258A (en) | Preparation method of oxalaggrin sodium and intermediate thereof | |
WO2012069423A1 (en) | Method for the preparation of naproxen chloride | |
EP2152697A2 (en) | Process for the preparation of alfuzosin and salts thereof | |
WO2013054273A2 (en) | Process for the preparation of agomelatine | |
JP2011515328A (en) | Efficient method for producing atorvastatin | |
WO2006082835A1 (en) | Method for producing theanine | |
CN101955464A (en) | 4-(4-methoxybenzylamino)-3-(5-nitro-4-thiocyanic acid pyrimidine-2-amino) benzonitrile, preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080042243.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10818263 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010297892 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2772681 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1968/DELNP/2012 Country of ref document: IN |
|
REEP | Request for entry into the european phase |
Ref document number: 2010818263 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010818263 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2010297892 Country of ref document: AU Date of ref document: 20100323 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012530106 Country of ref document: JP Ref document number: 13497544 Country of ref document: US Ref document number: MX/A/2012/003488 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20127010180 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012116208 Country of ref document: RU |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012006406 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012006406 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120321 |